Biogen

Bono: The fact that this was fast-tracked, and you're seeing this stock price, the fact that this seems to be moving forward in a positive direction says that this has been vetted perhaps more than we have really given credit for because of previous instances. Meg Terrell: I think people are a little concerned that Biogen at some point has a pipeline issue and is going to have to do some M&A. Bono: This kind of sets up one, positively for Biogen, two, for healthcare as an overall sector.